Effects and safety of 131I-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: results from a multicenter observational registry
K Yoshinaga, N Oriuchi, H Wakabayashi… - Endocrine …, 2014 - jstage.jst.go.jp
Effective treatments for malignant neuroendocrine tumors are under development. While
iodine-131 metaiodobenzylguanidine (131I-MIBG) radiotherapy has been used in the …
iodine-131 metaiodobenzylguanidine (131I-MIBG) radiotherapy has been used in the …
Feasibility and advantage of adding 131I-MIBG to 90Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors
DL Bushnell, MT Madsen, T O'cdorisio, Y Menda… - EJNMMI research, 2014 - Springer
Background Peptide receptor radionuclide therapy (PRRT) is an effective form of treatment
for patients with metastatic neuroendocrine tumors (NETs). However, delivering sufficient …
for patients with metastatic neuroendocrine tumors (NETs). However, delivering sufficient …